European Journal of Gynaecological Oncology
Real-world data on predictors of survival in patients with gynecological tumors following pelvic arterial embolization
By Camila S. S. Menezes, Jessé Lopes da Silva, Lucas Zanetti de Albuquerque and 5 others.
Abstract
Background
Uterine bleeding is a potentially life-threatening complication of gynecologic malignancies. Pelvic transarterial embolization (TAE) is used for hemorrhage control, but data on outcomes and prognostic factors remain limited. This retrospective study evaluated women treated with TAE in whom cervical cancer, endometrial cancer, and radiotherapy-induced pelvic sequelae were identified within the cohort.
Methods
Women who underwent TAE at the Brazilian National Cancer Institute (INCA) between 2019 and 2020 were included. Demographic and tumor characteristics, clinical response to TAE, and survival data were analyzed. Hemorrhage control was classified as a complete response (CR), temporary response (TempR), or no response (NR). Overall survival (OS) was estimated using the Kaplan-Meier method and compared according to response status (CR/TempR vs. NR), International Federation of Gynecology and Obstetrics (FIGO) stage (I–III vs. IV), and the presence of genitourinary fistulas.